Skip to main content
. 2022 May 13;23:S52–S59. doi: 10.1016/j.vacun.2022.04.003

Table 5.

COVID19-vaccine preference among vaccinated and non-vaccinated participants in the study.

COVID-19 vaccine preference Proportion (%)
Vaccinated individuals Non-vaccinated individuals Total
No preference 16.61 25.75 21.17
Sinovac/Sinopharm 31.89 28.43 30.17
Pfizer BioNTech 19.93 16.72 18.33
AstraZeneca 10.30 7.69 9
Sputnik V 8.31 12.37 3.53
Moderna 6.64 4.35 5.50
Johnson& Johnson 6.31 4.68 5.50